-
Global Biotechnology & Pharmaceutical Markets1 week agoMédunik and Biocodex sign exclusive agreement for Diacomit in Canada
The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Fauci speaks, and writes
Anthony Fauci is working on a book, we unpack Trump's latest drug pricing deals, and more from STAT's D.C. Diagnosis newsletter.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoChina’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoK2 Therapeutics: Spreading bets across range of Asia-sourced assets
BIOCENTURY | EMERGING COMPANY PROFILEK2 THERAPEUTICS: SPREADING BETS ACROSS RANGE OF ASIA-SOURCED ASSETSFormer Legend CEO Ying Huang looks to $250M series A while aiming to replicate...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: 5 burning questions on Trump’s latest deals with drugmakers
Here are some of the key questions about the agreements the Trump administration has reached with drugmakers on pricing.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Novartis gets multiple sclerosis win with BTK inhibitor
More Trump drug pricing deals, GSK speeds up development of mRNA flu vaccine, and other biotech news
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSTAT+: Trump strikes nine more deals with drugmakers to lower prices
President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
Psychedelic therapies ride wave of public favor into FDA hearing
After a brief storm of political headwinds, mRNA is back with strong momentum
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
